CHMA News and Press, Chiasma Inc. From 12/19/19

NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology In...

WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer, and William Ludlam, M.D., P...

WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D., Senior Vice President of Clinical D...

The following slide deck was published by Chiasma, Inc. in conjunction with this Read more ...

Chiasma, Inc. (CHMA) Q3 2019 Results Earnings Conference Call November 05, 2019, 05:00 PM ET Company Participants Dawn Schottlandt - Investor relations Raj Kannan - Chief Executive Officer Bill Ludlam - Senior Vice President-Clinical Development and Medical Affairs Mark Fitzpat...

Image source: The Motley Fool. Chiasma Inc   (NASDAQ: CHMA) Q3 2019 Earnings Call Nov 5, 2019 , 5:00 p.m. ET Operator Continue reading

Chiasma (NASDAQ: CHMA ): Q3 GAAP EPS of -$0.20 beats by $0.01 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA ® NDA on track for submission by year-end 2019 MPOWERED TM Phase 3 trial, designed to support EU approval, progressing as planned with top...

WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday...

WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...